Summit Therapeutics Inc.
SMMTNasdaq
$13.81
↑ +0.4%Jul 17 close · end-of-day
Price
1Y↓ -51.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.7B
Enterprise Value
$10.1B
P/E
—
P/S
—
P/B
19.6
EV/EBITDA
—
PEG
—
FCF Yield
-3.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$1.2B
Free Cash Flow (TTM)
-$384.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-220.9%
ROIC
—
Debt / Equity
—
Net Cash
$598.7M
Return 1Y
-50.0%
Company profile
Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.
- CEO
- Robert W. Duggan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- Florida
- Website
- summittxinc.com
Management & directors
- Duggan Robert WCo-Chief Executive Officer
- Zanganeh MakyCo-Chief Executive Officer
- Soni Manmeet SinghCOO and CFO
- Anand BhaskarChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
SMMT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.24↑ +166.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $860,000.00 | $1.8M | $705,000.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$53.2M | -$86.2M | -$72.1M | -$609.6M | -$226.0M | — |
| Net income | -$52.7M | -$88.6M | -$78.8M | -$614.9M | -$221.3M | -$1.1B |
| Diluted EPS | -$0.76 | -$0.67 | -$0.41 | -$0.99 | -$0.31 | -$1.44 |
| Operating cash flow | -$48.1M | -$72.6M | -$41.6M | -$76.8M | -$142.1M | -$322.9M |
| Free cash flow | -$48.5M | -$72.9M | -$42.2M | -$76.9M | -$142.2M | -$323.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -6185.2% | -4764.3% | -10225.4% | — | — | — |
| Net margin | -6127.6% | -4897.8% | -11174.8% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$59.6M | -$58.4M | -$65.6M | — | — | — | — | — |
| Net income | -$60.4M | -$56.3M | -$61.2M | -$62.9M | -$565.7M | -$231.8M | -$219.2M | -$189.4M |
| Diluted EPS | -$0.09 | -$0.08 | -$0.08 | -$0.09 | -$0.76 | -$0.31 | -$0.28 | -$0.24 |
| Operating cash flow | -$33.0M | -$30.3M | -$48.7M | -$61.2M | -$66.7M | -$93.1M | -$101.9M | -$122.3M |
| Free cash flow | -$33.1M | -$30.4M | -$48.7M | -$61.6M | -$66.7M | -$93.2M | -$102.1M | -$122.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-12 | Zanganeh Maky· Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | filing |
| 2026-06-12 | DUGGAN ROBERT W· Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | filing |
| 2026-06-04 | DUGGAN ROBERT W· Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | filing |
| 2026-06-04 | Zanganeh Maky· Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | filing |
| 2026-06-04 | Soni Manmeet Singh· COO and CFO | Buy | 25,000 | $14.46 | $361,500.00 | filing |
| 2026-06-04 | Soni Manmeet Singh· COO and CFO | Buy | 25,000 | $14.43 | $360,750.00 | filing |
| 2025-10-21 | DUGGAN ROBERT W· Co-Chief Executive Officer | Award | 13,980,789 | $18.74 | $262.0M | filing |
| 2025-10-21 | Zanganeh Maky· Co-Chief Executive Officer | Award | 13,980,789 | $18.74 | $262.0M | filing |
| 2025-10-21 | Xia Yu | Buy | 533,617 | $18.74 | $10.0M | filing |
| 2025-10-21 | Zanganeh Maky· Co-Chief Executive Officer | Award | 266,808 | $18.74 | $5.0M | filing |
| 2025-10-21 | DUGGAN ROBERT W· Co-Chief Executive Officer | Award | 266,808 | $18.74 | $5.0M | filing |
| 2025-10-21 | Soni Manmeet Singh· COO and CFO | Award | 53,361 | $18.74 | $999,985.14 | filing |
| 2025-10-21 | Anand Bhaskar· Chief Accounting Officer | Award | 26,680 | $18.74 | $499,983.20 | filing |
| 2025-10-21 | DUGGAN ROBERT W· Co-Chief Executive Officer | Buy | 26,680 | $18.74 | $499,983.20 | filing |
| 2025-10-21 | Zanganeh Maky· Co-Chief Executive Officer | Buy | 26,680 | $18.74 | $499,983.20 | filing |
| 2025-09-11 | Zanganeh Maky· Co-Chief Executive Officer | Buy | 5,000 | $18.07 | $90,350.00 | filing |
| 2025-09-11 | DUGGAN ROBERT W· Co-Chief Executive Officer | Buy | 5,000 | $18.07 | $90,350.00 | filing |
| 2025-09-10 | Zanganeh Maky· Co-Chief Executive Officer | Buy | 333,394 | $17.68 | $5.9M | filing |
| 2025-09-10 | DUGGAN ROBERT W· Co-Chief Executive Officer | Buy | 333,394 | $17.68 | $5.9M | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.